fbpx

QQQ
+ 2.31
364.32
+ 0.63%
BTC/USD
-805.39
60867.03
-1.31%
DIA
+ 3.70
345.43
+ 1.06%
SPY
+ 3.26
439.24
+ 0.74%
TLT
-0.85
146.73
-0.58%
GLD
-2.66
170.66
-1.58%

Tilray Adjourns Special Meeting Of Stockholders Until Sept. 10

August 19, 2021 3:19 pm
Share to Linkedin Share to Twitter Share to Facebook Share to Print License More
Tilray Adjourns Special Meeting Of Stockholders Until Sept. 10

Cannabis giant Tilray, Inc. (NASDAQ:TLRY)(TSX:TLRY) convened and then adjourned its special shareholders' meeting on Thursday, postponing it until Sept. 10, 2021.

Stockholders had intended to vote on two shareholder proposals: (1) a proposal to increase the authorized number of shares of common stock ("Authorized Shares Proposal"); and (2) a number of governance enhancements to increase stockholder rights (the "Governance Proposals").

The meeting, postponed several times, is intended to provide Tilray with additional time to solicit proxies and to give its shareholders more time to consider information relevant to the proposals, although votes already cast indicate there is sufficient support for both the Authorized Shares Proposal and the Governance Proposals.

MedMen Now In The Mix: With this week's announcement of Tilray’s strategic investment in MedMen convertible notes and the importance of Proposal 1 in enabling Tilray to optimize the execution of that transaction, Tilray's CEO is urging stockholders to vote immediately in support of long-term value creation.

Tilray announced on Tuesday it had acquired the majority of the outstanding senior secured convertible notes of MedMen Enterprises Inc. (CSE:MMEN) (OTCQX:MMNFF) in a transaction valued at $165.8 million.

"We urge stockholders who have not yet voted to participate in the success of their investment in Tilray by voting FOR all proposals on the agenda for the Special Meeting. By doing so, stockholders will be actively supporting Tilray’s ability to pursue and optimize growth opportunities, including our game-changing investment in MedMen convertible notes, expand and generate strong performance, increase stockholder rights and, ultimately, drive stockholder value," Irwin D. Simon, Tilray’s chairman and CEO said.

"No matter how many or how few shares you own, your participation will enable us to maximize our potential to create value for our stockholders in the near-term and in the future," Simon added.

The approval of the Authorized Shares Proposal requires the affirmative vote of holders of at least a majority of the voting power of shares outstanding and entitled to vote.

For the latest in financial news, exclusive stories, memes follow Benzinga on Twitter, Facebook & Instagram. For the best interviews, stock market talk & videos, subscribe to Benzinga Podcasts and our YouTube channel.


Related Articles

Ousted MedMen Executives File Suit Against Their Own Company

Ousted MedMen Executives File Suit Against Their Own Company

A company run by the ousted co-founders of cannabis giant MedMen (OTC: MMNFF), Adam Bierman and Andrew Modlin, are suing Coastal Holding Co., a company that holds several cannabis licenses in multiple California cities, over planning to sell the company for $56.2 million, reported Law360 read more
Tilray Acquires Majority Position In Amended MedMen Convertible Notes, Accelerating Path Into US Cannabis Market If Federal Legalization Occurs

Tilray Acquires Majority Position In Amended MedMen Convertible Notes, Accelerating Path Into US Cannabis Market If Federal Legalization Occurs

Tilray, Inc. (NASDAQ: TLRY), and MedMen Enterprises Inc. (CSE: MMEN) (OTCQX: MMNFF), announced on Tuesday Tilray has acquired the majority of MedMen’s outstanding senior secured convertible notes read more
Tilray's Q1 Revenue Grows 43% To $168M, Achieves 10th Consecutive Quarter Of Positive Adjusted EBITDA

Tilray's Q1 Revenue Grows 43% To $168M, Achieves 10th Consecutive Quarter Of Positive Adjusted EBITDA

Canadian cannabis giant Tilray, Inc. (NASDAQ: TLRY) (TSX: TLRY) released its financial results Thursday for the first fiscal quarter ended August 31, 2021, with net revenue of $168 million, up by 43% from $117 million in the same period of fiscal 2021. read more
Analysis: Aurora Cannabis Could Improve Position Based On Exports, Jushi Price Target Adjusted Down

Analysis: Aurora Cannabis Could Improve Position Based On Exports, Jushi Price Target Adjusted Down

Cantor Fitzgerald released two reports ahead of featured chats with the CEOs of Aurora Cannabis (NASDAQ: ACB) (TSX: ACB) and Jushi Holdings (CSE: JUSH) (OTCQX: JUSHF). read more